M. Issar et al., Determination of antifilarial compound UMF-078 and its metabolites in plasma by high-performance liquid chromatography, J CHROMAT B, 724(1), 1999, pp. 147-155
UMF-078, methyl (+/-)-[5-(alpha-amino-4-fluorobenzyl)benzimidazol-2-yl]carb
amate, is a new antifilarial compound being developed by the World Health O
rganization. In the present study, a HPLC method for the simultaneous estim
ation of UMF-078 and its metabolites (flubendazole, decarbamoylated flubend
azole, UMF060 and decarbamoylated UMF-060) in plasma was developed, validat
ed and applied to pharmacokinetic studies. Linearity was observed between 2
0 and 1000 ng/ml for decarbamoylated UMF-060 and between 10 and 500 ng/ml f
or other analytes. Recoveries were consistent over the concentration ranges
studied for all the analytes. Variations in intra- and inter-batch accurac
y and precision were within acceptable Limits of +/-20% at the lowest limit
of quantitation, whereas at higher concentrations it was +/-15%. The analy
tes showed stability up to two freeze-thaw cycles in plasma. No degradation
was observed for any of the analytes even after 72 h of storing the dry pl
asma extracts at -30 degrees C. The assay method was employed to study the
pharmacokinetics of hydrochloride salt of UMF-078 in rats. The parent compo
und and its metabolites viz: decarbamoylated UMF-060, UMF-060 and flubendaz
ole were quantitated in serum and the compounds could be monitored up to 16
8 h post-dose. (C) 1999 Elsevier Science B.V. All rights reserved.